PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Plast Surg 2011; 44(03): 467-473
DOI: 10.1055/s-0039-1699519
Original Article
Association of Plastic Surgeons of India

Severe idiosyncratic drug reactions with epidermal necrolysis: A 5-year study

I. O. Fadeyibi
Department of Surgery, Burns and Plastic Surgery Unit, College of Medicine/Lagos State University Teaching Hospital, Ikeja-Lagos, Nigeria
,
S. A. Ademiluyi
1   Department of Medicine, Burns and Plastic Surgery Unit, College of Medicine/Lagos State University Teaching Hospital, Ikeja-Lagos, Nigeria
,
F. O. Ajose
2   Department of Anatomy, Burns and Plastic Surgery Unit, College of Medicine/Lagos State University Teaching Hospital, Ikeja-Lagos, Nigeria
,
P. I. Jewo
3   Department of Obstetric and Gynecology, Burns and Plastic Surgery Unit, College of Medicine/Lagos State University Teaching Hospital, Ikeja-Lagos, Nigeria
,
O. I. Akinola
Department of Surgery, Burns and Plastic Surgery Unit, College of Medicine/Lagos State University Teaching Hospital, Ikeja-Lagos, Nigeria
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2019 (online)

Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

ABSTRACT

Introduction: Idiosyncratic drug reactions (IDRs) are unexpected responses to a drug. The spectrums of severe cutaneous reactions include Stevens–Johnson Syndrome (SJS), SJS/Lyell Syndrome and Toxic Epidermal Necrolysis (TEN). The conditions are associated with high mortality. This study was designed to determine the causal agents, patterns of presentations, review the management and make recommendations to reduce the incidence and mortality of this class of drug reactions. Materials and Methods: A retrospective study was made of patients seen with IDR in the Lagos State University Teaching Hospital, LASUTH, between January, 2004 and December, 2008. They were cases admitted with bullous skin eruptions with associated systemic symptoms. Results: Sixty-seven patients were seen, with 45 (67.2%) satisfying the inclusion criteria. Fifteen males and 30 females were involved, giving a male to female (M:F) ratio of 1:2. Their ages ranged from 7 to 79 years (mean, 40.02 ± 17.89 years). Peak incidences occurred among the 20–24 and 30–34 year age groups. The causal agents were antibiotics (48.89%), sulphonamides (24.44%), herbal preparations (17.78%) and artemisinin drugs (8.89%). Conclusions: The age groups with the peak incidence are the most likely to indulge more in drug abuse in environments with poor drug control. Diagnosis of SJS, SJS/TEN and TEN were missed in many patients at first contact due to the progressive nature of the conditions. Patients needed reviews at regular intervals when IDR was suspected. Health education to prevent drug abuse is important and herbal preparations should be scientifically studied to determine the efficacy and side-effects.

KEY WORDS

Idiosyncratic drug reactions - Stevens Johnson Syndrome - Toxic Epidermal Necrolysis - toxic epidermal necrolysis
 

  • REFERENCES

  • 1 British National Formulary 56. London: BMJ Group; 2008. p. 11.
  • 2 Leape LL, Breanan TA, Laird N. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Study II. N Engl J Med 1991;324:377-84.
  • 3 Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 2005;23:171-81.
  • 4 Alanko K, Stubb S, Kauppinan K. Cutaneous drug reactions: Clinical types and causative agents. A five-year survey of in patients (1981-1985). Acta Dem Venereol 1989;69:223-6.
  • 5 Fabbri P, Panconesi F. Erythema multiforme (minus and mains) and drug intake. Clin Dermatol 1993;11:479-89.
  • 6 Lyell A. Drug-induced toxic epidermal necrolysis: I. An overview. Clin Dermatol 1993;11:491-2.
  • 7 Castana O, Makrodimou M, Michelakis D, Tsandoulas Z, Alexakis D. Diseases mimicking a burn- Outcome and treatment. Ann Burn Fire Disasters 2005;18:130-2.
  • 8 Marinkovich MP. Blistering Diseases. Department of Dermatology, Stanford University School of Medicine. Available from: http://telemedicine.org/blister.htm . [last accessed on 2011 Apr 05].
  • 9 Brambilla G, Brucato F, Angrisano A, Palmieri G. Treatment of toxic epidermal necrolysis (TEN). Ann Burn Fire Disasters 2002;15:17-21.
  • 10 Atiyeh BS, Kayle DI, Nasser AA. Burn like syndromes. Ann Burns Fire Disasters 1999;12:39-43.
  • 11 Petkov T, Pehlivanov G, Grozdev I, Kavaklieva S, Tsankov N. Toxic epidermal necrolysis as a dermatological manifestation of drug hypersensitivity syndrome. Eur J Dermatol 2007;17:422-7.
  • 12 French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding. Int Immunopharmacol 2006;6:543-9.
  • 13 Cabral L, Riobom F, Diogo C. Toxic epidermal necrolysis. Ann Burn Fire Disasters 2004;17:90-102.
  • 14 Roujeau JC, Guillaume JC, Fabre JP, Penso D. Toxic epidermal necrolysis: Incidence and drug aetiology in France. Arch Dermatol 1996;126:37-43.
  • 15 Ugburo AO, Ilombu CA, Temiye EO, Fadeyibi IO, Akinola OI. Severe idiosyncratic reaction (Lyell Syndrome) after ingesting Dihydroartemisinin. Niger J Clin Pract 2009;12:224-7.
  • 16 Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell’s disease). Burns 2010;36:152-63.
  • 17 Spies M, Sanford AP, Wolf SE, Ail-Low JF, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Paediatrics 2001;108:1162-8.
  • 18 Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz P, Wolkenstein P. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
  • 19 Stern RS. Improving outcome of patient with toxic epidermal necrolysis and Steven-Johnson syndrome. Arch Dermaltol 2000;136:410-1.
  • 20 Becker DS. Toxic epidermal necrolysis. Lancet 1998;331:1417-20.
  • 21 Ugburo AO, Ilombu CA, Temiye EO. A 12-year retrospective study of non-burn skin loss (burn-like syndromes) at a tertiary burns unit in a developing country. Burn 2008;34:637-43.
  • 22 Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis and Stevens-Johnson Syndrome (SJS): Experience with high-dose intravenous immunoglobullins and topical conservative approach. A retrospective analysis. Burns 2007;33:452-9.
  • 23 De Smet PA. Herbal remedies. N Engl J Med 2002;347:2046-56.
  • 24 Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Int Med 1998;129:1061-5.
  • 25 Hewson MG. Traditional healers in Southern Africa. Ann Int Med 1998;128:1029-38.
  • 26 Awobusuyi JO. Alternative Medical Remedies in Clinic practice: Why do Patients use Native Medicines? Pharm J Lagos State Univ Teach Hosp 2006;1:3-5.
  • 27 Media Center Press Release-Prospectives in Health Magazine- PAHO Today. WHO Dihydroartemisinin Htm.
  • 28 Burgeson RE, Lunstrum GP, Rokosova B, Rimberg CS, Rosenbaum LM, Keene DR. The structure and function of type VII collagen. Ann NY Acad Sci 1990;580:32-43.
  • 29 McGee T, Munstard A. Toxic epidermal necrolysis syndrome: Mortality rate reduced by early referral to regional burn center. Plast Reconstr Surg 1998;102:1018-22.
  • 30 Acikel C, Eren F, Ergun O, Celikoz B. Topical treatment of toxic epidermal necrolysis using Omiderm and glycerol preserved human cadaver skin. Ann Burns Fire Disaster 2002;15:2.
  • 31 Jewo PI, Fadeyibi IO, Babalola OS, Saalu LC. A comparative study of the wound healing properties of Moist Exposed Burn Ointment (MEBO) and silver sulphadiazine. Ann Burns Fire Disaster 2009;22:79-82.
  • 32 Jurjus A, Atiyeh BS, Abdallah IM, Jurjus RA, Hayek SN, Jaoude MA, et al. Pharmacological modulation of wound healing in experimental burns. Burns 2007;33:892-907.
  • 33 Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005;153:241-53.